Danusertib is a potent inhibitor of Aurora kinases, which play a critical role in cell division and mitosis. Due to its ability to disrupt abnormal cell proliferation, it has been investigated primarily in oncology for the treatment of various cancers. It shows promise in targeting tumor cells with high mitotic activity, including in solid tumors and hematological malignancies such as leukemia and lymphoma. Its application is particularly explored in cases where cancer cells have developed resistance to other chemotherapeutic agents. Danusertib’s mechanism allows it to induce cell cycle arrest and apoptosis, making it a candidate for use in combination therapies to enhance the efficacy of existing anticancer drugs. Research is ongoing to evaluate its effectiveness and safety in clinical settings.